YFa, a chimeric opioid peptide, induces kappa-specific antinociception with no tolerance development during 6 days of chronic treatment

Journal of Neuroscience Research

Volumn 86, Issue 7, 2008, Pages 1599-1607

  Vats, Ishwar Dutt ^a,b   Dolt, Karamjit Singh ^a   Kumar, Krishan ^a,c   Karar, Jayashree ^a   Nath, Mahendra ^b   Mohan, Anita ^c   Pasha, M A Qadar ^a   Pasha, Santosh ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b UNIVERSITY OF DELHI   (India)

^c GURU GOBIND SINGH INDRAPRASTHA UNIVERSITY   (India)

Author keywords

Antinociception; Chimeric opioid peptide; Opioid receptors; Tail flick latency test

Indexed keywords

ENDOMORPHIN 1; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR; NALOXONAZINE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE PEPTIDE; TYROSYLGLYCYLGLYCYLPHENYLALANYLMETHIONYLLYSYLLYSYLLYSYLPHENYLALANYL METHIONYLARGINYLPHENYLALAMIDE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERANCE; LONG TERM CARE; MALE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TAIL FLICK TEST; UPREGULATION; WESTERN BLOTTING;

ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENKEPHALIN, METHIONINE; FMRFAMIDE; GENE EXPRESSION REGULATION; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; OLIGOPEPTIDES; PAIN MEASUREMENT; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; TIME FACTORS;

EID: 43149111300     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21605     Document Type: Article

References (38)

1. Allard M, Geoffre S, Legendre P, Vincent JD, Simonnet G. 1989. Characterization of rat spinal cord receptors to FLFQPQRFamide, a mammalian morphine modulating peptide: a binding study. Brain Res 500:169-176.
2. Bi J, Hu X, Loh HH, Wei LN. 2003. Mouse kappa-opioid receptor mRNA differential transport in neurons. Mol Pharmacol 64:594-599.
3. Brodsky M, Elliott K, Hynansky A, Inturrisi CE. 1995. CNS levels of mu opioid receptor (MOR-1) mRNA during chronic treatment with morphine or naltrexone. Brain Res Bull 38:135-141.
4. Burford NT, Tolbert LM, Sadee W. 1998. Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I. Eur J Pharmacol 342:123-126.
5. Castelli MP, Melis M, Mameli M, Fadda P, Diaz G, Gessa GL. 1997. Chrome morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain. Brain Res Mol Brain Res 45:149-153.
6. Chaturvedi K. 2003. Opioid peptides, opioid receptors and mechanism of down regulation. Indian J Exp Biol 41:5-13.
7. Evans CJ. 1998. The opioid peptides. In: Pasternak GW, editors. The opiate receptors. Clifton, NJ: Humana Press. p 23-74.
8. Galina ZH, Kastin AJ. 1986. Existence of antiopiate systems as illustrated by MIF-1/Tyr-MIF-1. Life Sci 39:2153-2159.
9. Goodman CB. 1995. Modulation of opioid receptors by anti-opioid peptides. In: The pharmacology of opioid peptides. Singapore, gmbh: Academic Publishers. p 303-319.
10. Gudehithlu KP, Tejwani GA, Bhargava HN. 1991. Beta-endorphin and methionine-enkephalin levels in discrete brain regions, spinal cord, pituitary gland and plasma of morphine tolerant-dependent and abstinent rats. Brain Res 553:284-290.
11. Gupta S, Pasha S, Gupta YK, Bhardwaj DK. 1999. Chimeric peptide of Met-enkephalin and FMRFa induces antinociception and attenuates development of tolerance to morphine antinociception. Peptides 20:471-478.
12. Harrison C, Rowbotham DJ, Grandy DK, Lambert DG. 2000. Endomorphin-1 induced desensitization and down-regulation of the recombinant mu-opioid receptor. Br J Pharmacol 131:1220-1226.
13. Horner KA, Zadina JE. 2004. Internalization and down-regulation of mu opioid receptors by endomorphins and morphine in SH-SY5Y human neuroblastoma cells. Brain Res 1028:121-132.
14. Johnson SM, Fleming WW. 1989. Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol Rev 41:435-488.
15. Law PY, Louie AK, Loh HH. 1985. Effect of pertussis toxin treatment on the down-regulation of opiate receptors in neuroblastoma X glioma NG108-15 hybrid cells. J Biol Chem 260:14818-14823.
16. Liu-Chen LY. 2004. Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sci 75:511-536.
17. Loh HH, Tao PL, Smith AP. 1988. Role of receptor regulation in opioid tolerance mechanisms. Synapse 2:457-462.
18. Malin DH, Lake JR, Fowler DE, Hammond MV, Brown SL, Leyva JE, Prasco PE, Dougherty TM. 1990a. FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 11:277-280.
19. Malin DH, Lake JR, Hammond MV, Fowler DE, Rogillio RB, Brown SL, Sims JL, Leecraft BM, Yang HY. 1990b. FMRF-NH2-like mammalian octapeptide: possible role in opiate dependence and abstinence. Peptides 11:969-972.
20. McConalogue K, Grady EF, Minnis J, Balestra B, Tonini M, Brecha NC, Bunnett NW, Sternini C. 1999. Activation and internalization of the mu-opioid receptor by the newly discovered endogenous agonists, endomorphin-1 and endomorphin-2. Neuroscience 90:1051-1059.
21. Nesder EJ. 1992. Molcular mechanisms of drug addiction. J Neurosci 12:2439-2450.
22. Pasternak GW. 1993. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 16:1-18.
23. Rattan AK, Koo KL, Tejwani GA, Bhargava HN. 1992. The effect of morphine tolerance dependence and abstinence on immunoreactive dynorphin (1-13) levels in discrete brain regions, spinal cord, pituitary gland and peripheral tissues of the rat. Brain Res 584:207-212.
24. Reisine T, Pasternak GW. 1996. Opioid analgesics and antagonists. In: Goodman and Gilman's: the pharmacological basis of therapeutics. New York: McGraw-Hill. p 521-556.
25. Rothman RB. 1992. A review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 12:129-138.
26. Tang J, Yang HY, Costa E. 1984. Inhibition of spontaneous and opiate-modified nociception by an endogenous neuropeptide with Phe-Met-Arg-Phe-NH2-like immunoreactivity. Proc Nad Acad Sci U S A 81:5002-5005.
27. Unterwald EM, Rubenfeld JM, Imai Y, Wang JB, Uhl GR, Kreek MJ. 1995. Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels. Brain Res Mol Brain Res 33:351-355.
28. Vankova ME, Weinger MB, Chen DY, Bronson JB, Mods V, Koob GF. 1996. Role of central mu, delta-1, and kappa-1 opioid receptors in opioid-induced muscle rigidity in the rat. Anesthesiology 85:574-583.
29. Wang Y, Li JG, Huang P, Xu W, Liu-Chen LY. 2003. Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cyclase superactivation is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation. J Pharmacol Exp Ther 307:1127-1134.
30. Wei LN, Hu X, Bi J, Loh H. 2000. Post-transcriptional regulation of mouse kappa-opioid receptor expression. Mol. Pharmacol. 57:401-408.
31. Wei LN, Loh HH. 2002. Regulation of opioid receptor expression. Curr Opin Pharmacol 2:69-75.
32. Wood PW, Iyengar S, Pasternak GW. 1998. Central actions of opiates and opioid peptides. In: The opiate receptors. Chiton, NJ: Humana Press. p 307-356.
33. Yang HY, Fratta W, Majane EA, Costa E. 1985. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc Natl Acad Sci U S A 82:7757-7761.
34. Zadina JE, Hackler L, Ge LJ, Kastin AJ. 1997a. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386:499-502.
35. Zadina JE, Hackler L, Ge LJ, Kastin AJ. 1997b. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386:499-502.
36. Zadina JE, Kastin AJ, Harrison LM, Ge LJ, Chang SL. 1995. Opiate receptor changes after chronic exposure to agonists and antagonists. Ann N Y Acad Sci 757:353-361.
37. Zhang F, Li J, Li JG, Liu-Chen LY. 2002. (-)U50,488H [(trans)-3,4- dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneace tamide] induces internalization and down-regulation of the human, but not the rat, kappa-opioid receptor: structural basis for the differential regulation. J Pharmacol Exp Ther 302:1184-1192.
38. Zhu J, Luo LY, Mao GF, Ashby B, Liu-Chen LY. 1998. Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 285:28-36.